Figure 2

Kaplan–Meier curves of (a) progression-free-survival (PFS) and (b) overall survival (OS) with first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in two groups of patients who received minocycline (MINO) for skin rash as an adverse event of EGFR-TKIs (MINO group) and those who did not (control group). NR not reached.